|Jakarta - International Pharmaceutical Manufacturers Group (IPMG), a non-profit organization that comprises 24 international research-based pharmaceutical companies operating in Indonesia, today organizes a focus group discussion titled “The Future of SJSN under the New Government, 2014-2019 Period”.
The discussion underlines IPMG’s commitment to supporting the development of and providing input for improving Indonesia’s healthcare system.
Social insurance has remained a national issue despite constitutional guarantees of access to social coverage and emphasis on the role of the state in providing universal social coverage, including access to a better healthcare system. The National Social Insurance System (SJSN) for health coverage that became effective on January 1, 2014 and that is aimed at reforming Indonesia’s healthcare system has yet to yield the desired results. The new government that will be installed in October 2014 will be responsible for dealing with the challenges faced by the Health Insurance Provider (BPJS). The success or failure of the health reform will rest entirely on the new government’s role in implementing the core principles of the healthcare system.
“The new government should make the national health program a priority in its agenda, in line with the aspirations related to the universal health coverage. The promise of the president-elect to improve basic infrastructure, including health infrastructure, during his campaign is a political promise that must be realized. To that end, IPMG supports the new government in continuing and improving the National Health Insurance (JKN) program in an effort to improve the healthcare system and eliminate inequality in the health sector, as well as to guarantee access to healthcare for all,” IPMG Chairman Luthfi Mardiansyah said.
The next government should guarantee the sustainability of the SJSN, which is crucial for the people and for improving the quality of Indonesia’s healthcare system. The goal of achieving high quality healthcare and translating the general principles related to the role of the government into action requires a solid effort by and cooperation between the public and private sectors.
The discussion presents experts from various fields as speakers, including Deputy Health Minister Ali Ghufron Mukti, Director of Pharmaceutical Services at the Health Ministry Bayu Teja Muliawan, Chairman of the National Council on Social Welfare (DJSN) Chazali H. Situmorang, BPJS Research and Development Head Togar Siallagan, former PT Askes director of operations Umbu Marisi, and Chairman of the Association of Indonesian Social Security and Health Experts (PAMJAKI) Rosa Ch. Ginting.
Several healthcare organizations such as GP Farmasi, IDI, Persi, IAI, LKPP, ARSADA and ARSSI also join the disucssion.
"IPMG believes that the success of the JKN program rests on several factors including financing, a balanced role of stakeholders, and solid public-private partnership. IPMG fully supports the government’s effort to apply a healthcare system that has a positive effect on the Indonesian people and at the same time ensures the sustainability of the program," Luthfi said.
In addition, to ensure the success and effectiveness of the JKN program, the treatment of patients should be made a priority. Ineffective medication could result in a long process of recovery that in turn leads to higher cost of treatment. This leads to the question of how to ensure a long-term success of the program.
Speaking on the sidelines of the media discussion, Luthfi pointed out that “Every patient has the right to healthcare, including the right to access effective, high quality and efficacious medicines. It is the responsibility of healthcare providers to respect the right of patients and recognize their different needs. Therefore, it is important to ensure that patients have access to medicines that serve their needs.”
Chairman of the National Council on Social Welfare (DJSN) Chazali H. Situmorang on the occasion drew attention to the crucial role of the BPJS and the Health Ministry in evaluating the implementation of the the SJSN program and ensuring its fundamental improvement. "Transparency, better services, and substantial improvement are important factors in the effort to improve the implementation and sustainaibility of the SJSN program.”
Deputy Health Minister Ali Ghufron Mukti said that the government strives to improve the quality of healthcare in line with the goal of the JKN program.”
Director of Pharmaceutical Services at the Health Ministry Bayu Teja Muliawan said that despite some drawbacks, the Health Ministry is confident of meeting the SJSN target in 2019.
BPJS Research and Development Head Togar Siallagan said that to improve healthcare services under the JKN program, the next government should ensure policy certainty related to the future of the SJSN program, including the technical aspects of its implementation, a guarantee that there will be no changes in policy implementation from Sabang to Merauke, and evaluation as well as supply and availability of drugs required for the program.
Speaking of public expectation of the new government, Togar Siallagan said that BPJS Kesehatan seeks to improve the quality of healthcare service under the SJSN program. “As a state institution, BPJS will give input based on our evaluation. BPJS believes that the next leader in the new government will guarantee equal access to healthcare, not just any kind of healthcare but quality healthcare that is able to improve the health status of the entire nation.”
IPMG is a non-profit organization that comprises 24 international research-based pharmaceutical companies operating in Indonesia. IPMG was established in August 2002.
IPMG members and their headquarters continuously invest in research and development to bring the latest innovation in medicines that are safe and produced in accordance to the international standard of quality to Indonesia.
Since 1999 IPMG members have introduced more than 250 new products to Indonesia to treat cancer, infectious diseases, cardiovascular diseases and other diseases. IPMG members today employ about 10,000 people in their operations.
IPMG strives to combat and help eradicate counterfeit drugs by raising public awareness of the danger of counterfeit drugs.
IPMG is an active member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the Indonesian Chambers of Commerce (KADIN).
For more information, contact:
International Pharmaceutical Manufacturers
T: +62 21 769 7531
F: +62 21 769 7532
M: +62 856 933 20 156
T: +62 21 5296 3880 ext. 305
F: +62 21 5296 3881
M: +62 818 0225 4971